Discover effective strategies to minimize sickle cell pain crises and avoid hospitalizations. Leading hematologists share ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

OXBRYTA was being used fairly widely ... As you're aware, I'm sure there haven't been drugs previously approved for sickle cell on the basis of HbF induction alone, but we believe that there ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA ...

In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta (voxelotor) for sickle cell disease (SCD) in all markets where it is approved. Pfizer's decision is based on the totality of ...

Despite a quarterly revenue dip, Fulcrum Therapeutics Inc (FULC) strengthens its cash position and advances key programs, ...

Back in September, the company decided to stop distributing the sickle cell disease treatment Oxbryta after a phase 3 trial turned up some concerning results.